Navigation Links
Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
Date:1/27/2009

BELLEVUE, Wash., Jan. 27 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the election of former Commissioner of the FDA, Frank Young, M.D., Ph.D., to a newly created seat on its board of directors.

Dr. Young has held positions in clinical practice, academia and government, including Commissioner of the FDA from 1984 to 1989. He has also served as a corporate, venture finance, and regulatory consultant. He was the U.S. Representative to the Executive Committee of the World Health Organization, as well as Dean of the School of Medicine and Dentistry, Director of the Medical Center, and Vice President for Health Affairs at the University of Rochester in New York. Dr. Young is presently a partner at Essex Woodlands Health Ventures, an investor in Light Sciences Oncology. He received his medical doctorate from Upstate Medical University, New York, and a Ph.D. from Case Western Reserve University. His internship and residency in Pathology was at University Hospitals in Cleveland, Ohio.

"Dr. Young's unique experience and perspective on industry and regulatory issues will be particularly useful as we approach a potential NDA submission in 2009 for Light Infusion Therapy as a treatment for primary liver cancer, and in 2010 as a treatment for metastatic colorectal cancer," said Llew Keltner, M.D., Ph.D., president and CEO of Light Sciences Oncology.

"I am especially excited to join the Light Sciences Oncology board of directors at this pivotal time for the company and its products under development," added Dr. Young. "I am looking forward to sharing my experience over a long career to help LSO reach its goal of providing a revolutionary therapy to cancer patients."

About Light Sciences Oncology

Light Sciences Oncology (LSO) is the developer of Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment for solid tumors and other conditions. The drug treatment is activated by a palm-sized, single-use, disposable unit designed to provide easy use for physicians and tolerable, effective, and repeatable treatments for patients. LSO has completed enrollment of patients in a Phase 3 trial of Litx in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO has also completed a Phase 1/2 trial and has initiated a Phase 2a trial in benign prostatic hyperplasia (BPH), or enlargement of the prostate. LSO's development organization oversees engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.

Contacts

     Robert M. Littauer
     Vice President, Chief Financial Officer and Treasurer
     425-957-8900
     bobl@lsoncology.com

     Llew Keltner, M.D., Ph.D.
     President and CEO
     425-957-8900
     dr_llew@lsoncology.com

Website: www.lsoncology.com

Light Infusion Therapy(TM), Litx(TM), and LS11(R) are trademarks of Light Sciences Oncology, Inc.


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. Study shines more light on benefit of vitamin D in fighting cancer
3. Bacteria See the Light
4. Quantum light beams good for fast technology
5. Free will takes flight: how our brains respond to an approaching menace
6. New MRI finding sheds light on multiple sclerosis disease progressio
7. RA Drugs Linked to Slight Skin Cancer Risk
8. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
9. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
10. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
11. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: